For: | Li H, Fu ZY, Arslan ME, Cho D, Lee H. Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: A comprehensive review. World J Exp Med 2021; 11(6): 79-92 [PMID: 36246150 DOI: 10.5493/wjem.v11.i6.79] |
---|---|
URL: | https://www.wjgnet.com/2220-315x/full/v11/i6/79.htm |
Number | Citing Articles |
1 |
Masashi Kono, Yoriaki Komeda, Hisato Kawakami, Satoru Hagiwara, George Tribonias, Kohei Handa, Shunsuke Omoto, Mamoru Takenaka, Hiroshi Kashida, Naoko Tsuji, Masatoshi Kudo. JAK Inhibitor Upadacitinib Induces Remission in Refractory Immune‐Related Colitis Triggered by CTLA‐4 and PD‐1 Inhibitor Combination Therapy in Malignant Pleural Mesothelioma: A Case Report. Cancer Reports 2024; 7(10) doi: 10.1002/cnr2.70032
|
2 |
Maria Terrin, Giulia Migliorisi, Arianna Dal Buono, Roberto Gabbiadini, Elisabetta Mastrorocco, Alessandro Quadarella, Alessandro Repici, Armando Santoro, Alessandro Armuzzi. Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management. International Journal of Molecular Sciences 2023; 24(14): 11504 doi: 10.3390/ijms241411504
|
3 |
O. Gómez Escudero. Enterocolitis and other immunotherapy and targeted therapy-related gastrointestinal manifestations: A review for gastroenterologist. Revista de Gastroenterología de México (English Edition) 2024; 89(1): 89 doi: 10.1016/j.rgmxen.2023.11.001
|
4 |
Antonietta Gerarda Gravina, Raffaele Pellegrino, Alfonso Esposito, Marina Cipullo, Mario Romeo, Giovanna Palladino, Patrizia Iodice, Alessandro Federico, Teresa Troiani. The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review. Cancers 2024; 16(3): 611 doi: 10.3390/cancers16030611
|
5 |
O. Gómez-Escudero. Enterocolitis y otras manifestaciones de toxicidad gastrointestinal asociada a inmunoterapia y terapia blanco: una revisión para el gastroenterólogo. Revista de Gastroenterología de México 2024; 89(1): 89 doi: 10.1016/j.rgmx.2023.11.001
|
6 |
Marianne Zoghbi, Kathryn J. Burk, Elio Haroun, Maria Saade, Maria Teresa Cruz Carreras. Immune checkpoint inhibitor-induced diarrhea and colitis: an overview. Supportive Care in Cancer 2024; 32(10) doi: 10.1007/s00520-024-08889-2
|
7 |
Sara Kiparizoska, Megan E. Murphy, Mark C. Mattar. Check this out: treatment paradigms in immune-checkpoint inhibitor colitis. Current Opinion in Gastroenterology 2023; 39(1): 43 doi: 10.1097/MOG.0000000000000892
|
8 |
Casey Fazer-Posorske, Lisa Kottschade, Anna Schwecke. The Basics of Cancer Immunotherapy. 2024; : 179 doi: 10.1007/978-3-031-59475-5_14
|
9 |
Skaistė Astašauskaitė, Rita Kupčinskaitė-Noreikienė, Inga Zaborienė, Rūta Vaičiūnienė, Tomas Vanagas, Darius Pranys, Lina Poškienė, Elona Juozaitytė. Multiorgan Toxicity from Dual Checkpoint Inhibitor Therapy, Resulting in a Complete Response—A Case Report. Medicina 2024; 60(7): 1129 doi: 10.3390/medicina60071129
|
10 |
Andreja Ocepek. Colitis due to cancer treatment with immune check-point inhibitors – review of literature and presentation of clinical cases. Radiology and Oncology 2024; 58(2): 179 doi: 10.2478/raon-2024-0022
|
11 |
Masaya Iwamuro, Takehiro Tanaka, Shunsuke Kagawa, Shoko Inoo, Motoyuki Otsuka. Collagenous Colitis in a Patient With Gastric Cancer Who Underwent Chemotherapy. Cureus 2023; doi: 10.7759/cureus.39466
|
12 |
Angelo Del Gaudio, Federica Di Vincenzo, Valentina Petito, Maria Cristina Giustiniani, Antonio Gasbarrini, Franco Scaldaferri, Loris Riccardo Lopetuso. Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach. Inflammatory Bowel Diseases 2024; 30(6): 1018 doi: 10.1093/ibd/izad229
|